The agenda features a mix of clinical updates and lively debates on provocative scientific topics in the field.
Treatment Considerations for Endocrine-Sensitive Patients With HR+/HER2- Metastatic Breast Cancer Speaker: Anne O’Dea, MD
An Overview of a Treatment for Patients with Previously Treated Recurrent or Metastatic Cervical Cancer Speaker: Tiffany Redfern, MD, FACOG
Title: A 2L Treatment Option for HR+/HER2− aBC or mBC With PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET ± CDK4/6i Speaker: Jeffrey B. Hargis, MD, FACP
Title: HER2 Expression Informs Clinical Decision Making in HER2-Low and HER2+ mBC Speaker: Kit Lu, MD
Supported by an educational grant from AstraZeneca.
Title: Addressing the Needs of Patients Across the HR+/HER2- Landscape: The Role of KISQALI in eBC and mBC Speaker: Scott Cash
Supported by an educational grant from ImmunoGen, Inc.
